Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc, a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for 221.50 USD per share in cash, for a total transaction value of approximately 9.2 billion USD.